Fluciclatide is an arginine-glycine-aspartic acid peptide with high affinity for αvβ3/αvβ5 integrin, which can be radiolabeled for PET imaging of angiogenesis. We showed that [18F]-Fluciclatide PET imaging can be conducted with high reproducibility in several tumour types including breast and colorectal cancer. Furthermore, we showed that in platinum-resistant/refractory ovarian cancer receiving combination therapy followed by maintenance pazopanib, [18F]Fluciclatide-PET uptake parameters can predict clinical outcome with pazopanib therapy indicating an anti-angiogenic response.
The ECMC supported the test and re-test studies of this imaging agent across multiple ECMCs (Kings, Bart’s, Oxford and UCL) and international sites with GE Healthcare as the industrial sponsor.
(Sharma R, et al., Eur J Nucl Med Mol Imaging. 2020 doi: 10.1007/s00259-019-04532-z. Epub 2019 Nov 21. PMID: 31754793; Sharma R, et al., J Nucl Med. 2015 doi: 10.2967/jnumed.115.158253. Epub 2015 Sep 17, PMID: 26383153).
REI-EXCISE, a feasibility study, aimed to evaluate the diagnostic accuracy of rapid ionisation mass spectroscopy using an iKnife device. REI-EXCISE trial has successfully recruited 158 patients and it is now in the close out phase, with ongoing data analysis. This study may help to reduce positive margins and improve the way breast conserving surgery is performed.
ECMC supported the early development of this technology on patient samples and then the early trials across both Imperial and the RMH ECMC sites.
(St John ER, et al., Breast Cancer Res. 2017 May 23;19(1):59. doi: 10.1186/s13058-017-0845-2. PMID: 28535818; Balog J, et al., Sci Transl Med. 2013 Jul 17;5(194):194ra93. doi: 10.1126/scitranslmed.3005623. PMID: 23863833).